Comprehensive Tumor Profiling

Caris molecular profiling utilizes a comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions.
dna-solid-lt-blue-fl-sky.svg

DNA

Whole Exome Sequencing (SNVs, Indels, Copy Number Alterations, Karyotyping & Viruses)

rna-solid-lt-blue-connect-sky.svg

RNA

Whole Transcriptome Sequencing (Gene Fusions and Variant Transcripts)

protein-solid-lt-sky-blue.svg

Protein

Immunohistochemistry (Tumor Relevant Protein Biomarkers)

Technical Specifications

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.

FFPE/SLIDE TISSUE

Tumor content: >20% tumor nuclei


Paraffin Block (Preferred)

Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)


Unstained Slides

25 slides

FRESH TISSUE

10% neutral buffered formalin


Four to six (4-6) biopsies with 18 gauge needle preferred


Six to ten (6-10) biopsies with 22 needle accepted

Caris Report Specs

Biomarker Analysis by Tumor Type

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.

Download Profile Menu for US and Intl PDF >

Download Profile Menu for New York State PDF >

Download Profile Menu for Europe PDF >

Looking for a Specific Gene?

Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.

Search Genes >

General Profile Menu (see above links for market specific menus)

All Biomarker Analysis includes:

Whole Exome Sequencing (WES)

DNA
Genomic
Signatures
Others
Point Mutations
Indels
Copy Number Alterations
HPV 16 and 18
MSI
TMB
LOH
HLA*
*Not available in New York state

Whole Transcriptome Sequencing (WTS)

RNA
Fusion Analysis
Variant Transcripts

Additional Testing:

Select tumor type to see specific tests to be performed.

Tumor Type:
No tumor selected
Tumor Type:
Select tumor type to see specific tests to be performed

Additional Information:

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

REFLEX TESTING MENU >

Tumor Type:
Select tumor type to see specific tests to be performed

Request Clinical/Scientific MSL Support

Please complete the form below to have a Caris Scientific Rep (Molecular Science Liaison) contact you directly.

"*" indicates required fields

Name*
Preferred contact method*

Order a test

Place an order today for a comprehensive, personalized Caris profiling report.